By altering the miR-362-5p/NOL4L pathway, the knockdown of circPDE5A at least partially inhibits the malignant evolution of NB, suggesting circPDE5A as a potential therapeutic target for NB and offering some evidence for its usage. The gene discussed is NOL4L; the disease is neuroblastoma.